---
title: "Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day"
description: "Vertex Pharmaceuticals Inc. (VRTX) shares rose 3.48% to $496.83 on a day when the overall stock market declined, with the S&P 500 down 0.43% and the Dow Jones down 1.05%. This increase ended a two-day"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277251690.md"
published_at: "2026-02-27T21:38:52.000Z"
---

# Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

> Vertex Pharmaceuticals Inc. (VRTX) shares rose 3.48% to $496.83 on a day when the overall stock market declined, with the S&P 500 down 0.43% and the Dow Jones down 1.05%. This increase ended a two-day losing streak, although the stock remains 4.40% below its 52-week high of $519.68. Compared to competitors, Vertex outperformed AbbVie Inc. (up 3.29%), while Krystal Biotech Inc. and Arcturus Therapeutics Holdings Inc. saw declines.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. (VRTX) rallied 3.48% to $496.83 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.43% to 6,878.88 and Dow Jones Industrial Average falling 1.05% to 48,977.92.

The stock's rise snapped a two-day losing streak.

Vertex Pharmaceuticals Inc. closed 4.40% below its 52-week high of $519.68, which the company reached on March 14th.

The stock outperformed some of its competitors Friday, as AbbVie Inc. (ABBV) rose 3.29% to $232.08, Krystal Biotech Inc. (KRYS) fell 0.26% to $275.64, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.08% to $8.23.

Trading volume (1.8 M) eclipsed its 50-day average volume of 1.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 27, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-27-26 1638ET

### Related Stocks

- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [VRTX.US - Vertex Pharma](https://longbridge.com/en/quote/VRTX.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [ABBV.US - Abbvie](https://longbridge.com/en/quote/ABBV.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference | Alumis (NASDAQ:ALMS) executives presented Phase 3 psoriasis results for envudeucitinib at the Oppenheimer Healthcare Con | [Link](https://longbridge.com/en/news/277123919.md) |
| UK's NICE Recommends AbbVie's Follicular Lymphoma Drug | UK's NICE Recommends AbbVie's Follicular Lymphoma Drug | [Link](https://longbridge.com/en/news/276614234.md) |
| Dror Ortho-Design, Inc. SEC 10-K Report | Dror Ortho-Design, Inc. has released its annual 10-K report, detailing its financial performance and strategic initiativ | [Link](https://longbridge.com/en/news/277226243.md) |
| This Is What Whales Are Betting On Moderna | Whales are taking a bearish stance on Moderna (NASDAQ:MRNA), with 42% of trades being bearish and 35% bullish. The total | [Link](https://longbridge.com/en/news/277243427.md) |
| 14:53 ETNuvia Dental Implant Center Named in Top10 Best Companies to Watch 2026 by BizTech Outlook | Nuvia Dental Implant Center has been recognized by BizTech Outlook as one of the "10 Best Companies to Watch 2026" for i | [Link](https://longbridge.com/en/news/277089366.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.